B. Metzler seel. Sohn & Co. Holding AG Takes $344,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 960 shares of the biotechnology company’s stock, valued at approximately $344,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Comerica Bank boosted its holdings in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after acquiring an additional 9,244 shares during the period. Tri Locum Partners LP purchased a new position in United Therapeutics during the 2nd quarter worth $15,959,000. QRG Capital Management Inc. grew its position in United Therapeutics by 12.4% during the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of United Therapeutics by 1.1% in the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after buying an additional 22,978 shares during the last quarter. Finally, Vontobel Holding Ltd. boosted its stake in shares of United Therapeutics by 90.4% during the third quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company’s stock worth $596,000 after buying an additional 790 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on UTHR shares. The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $370.86.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $1,034,510.88. This trade represents a 85.34 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 117,227 shares of company stock worth $43,671,320 over the last quarter. 11.90% of the stock is currently owned by insiders.

United Therapeutics Trading Up 1.5 %

NASDAQ:UTHR opened at $372.89 on Monday. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The firm has a market cap of $16.65 billion, a price-to-earnings ratio of 16.38, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. The company’s 50-day moving average is $365.06 and its two-hundred day moving average is $332.32.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.38 earnings per share. On average, equities research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.